Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines against Pediatric Infectious Diseases
share announcement

Vaccines against Pediatric Infectious Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 3869

Special Issue Editor

Dr. Parveen Fathima

E-Mail Website
Guest Editor
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, The University of Western Australia, Sydney, Australia
Interests: rotavirus vaccine; vaccine effectiveness; vaccine safety; rotavirus gastroenteritis; influenza; infectious disease epidemiology; infectious disease surveillance

Special Issue Information

Dear Colleagues,

Gastroenteritis is a leading cause of morbidity in young children worldwide in both developed and developing countries. In Western Australia, gastroenteritis is the second most common infection-related cause of hospitalisation in young children after acute lower respiratory infections. Globally, rotavirus is the most common cause of severe dehydrating gastroenteritis in young children. Rotavirus vaccines are now available to combat this childhood infectious disease. Vaccine efficacy and safety deserve further research. 

We have set up this Special Issue which focuses on the rotavirus vaccine, on vaccine immunogenicity, and on reduction in episodes of gastroenteritis. We also welcome vaccine design against rotavirus. All manuscripts will follow standard journal peer-review practices. We look forward to receiving your contributions to the Special Issue.

Dr. Parveen Fathima
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rotavirus vaccine
  • vaccine effectiveness
  • vaccine safety
  • rotavirus gastroenteritis
  • influenza
  • infectious disease epidemiology
  • infectious disease surveillance

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

21 pages, 3289 KiB  
Article
The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country
by Baudouin Standaert
Vaccines 2023, 11(5), 917; https://doi.org/10.3390/vaccines11050917 - 28 Apr 2023
Cited by 2 | Viewed by 1632
Abstract
Rotavirus vaccination was introduced in high-income countries starting in 2006, with no recommendation for optimal implementation. Economic evaluations were presented before launch projecting potential impacts. Few economic reassessments have been reported following reimbursement. This study compares the short- to long-term economic value of [...] Read more.
Rotavirus vaccination was introduced in high-income countries starting in 2006, with no recommendation for optimal implementation. Economic evaluations were presented before launch projecting potential impacts. Few economic reassessments have been reported following reimbursement. This study compares the short- to long-term economic value of rotavirus vaccination between pre-launch predictions and real-world evidence collected over 15 years, proposing recommendations for optimal vaccine launch. A cost-impact analysis compared rotavirus hospitalisation data after the introduction of vaccination between pre-launch modelled projections and observed data collected in the RotaBIS study in Belgium. A best model fit of the observed data was used to simulate launch scenarios to identify the optimal strategy. Data from other countries in Europe were used to confirm the potential optimal launch assessment. The Belgian analysis in the short term (first 8 years) indicated a more favourable impact for the observed data than predicted pre-launch model results. The long-term assessment (15 years) showed bigger economic disparities in favour of the model-predicted scenario. A simulated optimal vaccine launch, initiating the vaccination at least 6 months prior the next seasonal disease peak with an immediate very high vaccine coverage, indicated important additional potential gains, which would make vaccination very cost impactful. Finland and the UK are on such a route leading to long-term vaccination success, whereas Spain and Belgium have difficulties in achieving optimum vaccine benefits. An optimal launch of rotavirus vaccination may generate substantial economic gains over time. For high-income countries that are considering implementing rotavirus vaccination, achieving an optimal launch is a critical factor for long-term economic success. Full article
(This article belongs to the Special Issue Vaccines against Pediatric Infectious Diseases)
►▼ Show Figures

Figure 1

16 pages, 1248 KiB  
Article
Comparison of Immunogenicity and Safety of Diphtheria–Tetanus–Pertussis–Hepatitis B–Haemophilus influenza B (Bio Farma) with Pentabio® Vaccine Primed with Recombinant Hepatitis B at Birth (Using Different Source of Hepatitis B) in Indonesian Infants
by Eddy Fadlyana, Kusnandi Rusmil, Meita Dhamayanti, Rodman Tarigan, Cissy B. Kartasasmita, Rini Mulia Sari, Muhammad Gilang Dwi Putra and Hadyana Sukandar
Vaccines 2023, 11(3), 498; https://doi.org/10.3390/vaccines11030498 - 21 Feb 2023
Cited by 2 | Viewed by 1954
Abstract
Satisfying the needs of the national immunization program requires maintaining diphtheria–tetanus–pertussis (DTP)–hepatitis B (HB)–Haemophilus influenza B (Hib) production. Therefore, new hepatitis B sources are needed. This study aimed to evaluate the immunogenicity of the DTP–HB–Hib vaccine (Bio Farma) that used a different [...] Read more.
Satisfying the needs of the national immunization program requires maintaining diphtheria–tetanus–pertussis (DTP)–hepatitis B (HB)–Haemophilus influenza B (Hib) production. Therefore, new hepatitis B sources are needed. This study aimed to evaluate the immunogenicity of the DTP–HB–Hib vaccine (Bio Farma) that used a different source of hepatitis B. A prospective randomized, double-blind, bridging study was conducted. Subjects were divided into two groups with different batch numbers. Healthy infants 6–11 weeks of age at enrollment were immunized with three doses of the DTP–HB–Hib vaccine after a birth dose of hepatitis B vaccine. Blood samples were obtained prior to vaccination and 28 days after the third dose. Adverse events were recorded until 28 days after each dose. Of the 220 subjects, 205 (93.2%) completed the study protocol. The proportion of infants with anti-diphtheria and anti-tetanus titers ≥ 0.01 IU/mL was 100%, with anti-HBsAg titers ≥ 10 mIU/mL was 100%, and with Polyribosylribitol Phosphate-Tetanus Conjugate (PRP-TT) titers > 0.15 µg/mL was 96.1%. The pertussis response rate was 84.9%. No serious adverse events related to the study vaccine occurred. The three-dose DTP–HB–Hib vaccine (Bio Farma) is immunogenic, well tolerated, and suitable to replace licensed-equivalent vaccines. Full article
(This article belongs to the Special Issue Vaccines against Pediatric Infectious Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop